Cold Atmospheric Plasma Device Extension Study

NCT05937672 | Recruiting Phase 3 FDA Device

• 1 other identifier: Pro00127338
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

Conditions

Verruca Vulgaris; Molluscum Contagiosum

Keywords

Plasma; Warts; Molluscum; Pediatric; Dermatology

Outcome Measures

Primary Outcomes (4)

• Number of lesions with no response

  Absence of change in appearance of targeted lesion. Molluscum is defined as the visualization of a central umbilication with polylobular, white to yellow, amorphous structures. A peripheral crown of radiating or punctiform vessels may also be present. Warts are defined as grouped papillae, with dotted or loop vessels, and/or hemorrhagic points and lines often surrounded by a whitish halo.

  Maximum of 12 months

• Number of lesions with partial response

  There is change in the size, dyspigmentation, or discomfort of the targeted lesion as compared to its appearance and symptoms at the initial visit, but the lesion remains grossly visible. Molluscum is defined as the visualization of a central umbilication with polylobular, white to yellow, amorphous structures. A peripheral crown of radiating or punctiform vessels may also be present. Warts are defined as grouped papillae, with dotted or loop vessels, and/or hemorrhagic points and lines often surrounded by a whitish halo. Changes in the characteristics of the targeted lesions will be evaluated by a dermatologist and documented via photographs at follow-up visits at 4, 8, and 12 weeks, with the final outcome measured at the 12-week visit.

  Maximum of 12 months

• Number of lesions with complete response

  Targeted lesion is no longer grossly visible.

  Maximum of 12 months

• Number of treatments to complete lesion resolution

  Comparing number of treatments necessary for complete response.

  Maximum of 12 months

Secondary Outcomes (2)

• Adverse events from CAP tolerability questionnaire

  Maximum of 12 months

• Average score of visual analogue scale associated with treatment

  Maximum of 12 months

Study Arms (1)

Cold Atmospheric Plasma (CAP)

EXPERIMENTAL

We are proposing an open-label extension study of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.

Device: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)

Interventions

Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP) DEVICE

The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.

Also known as: Non-thermal atmospheric pressure plasma (NTAP)

Cold Atmospheric Plasma (CAP)

Eligibility Criteria

• Age: 4 Years - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• All patients from 4-21 years old with at least 1 lesion of vercurra or molluscum.
• Willingness of the participant and their guardian to provide consent when applicable.

You may not qualify if:

• Unwillingness to participate in the study
• Received any treatment on the lesion in the past month determined by review of their medical record
• Immunodeficiency determined by review of their medical record.
• Adverse response to prior treatments determined by review of medical record.
• Signs of self-resolution determined by study team members.
• Conditions that lead to excessive scarring determined by study team members.
• Face and genital lesions determined by study team members.

Sponsors & Collaborators

• Medical University of South Carolina: lead
• The Skin Center Dermatology Group: collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

RECRUITING

MeSH Terms

Conditions

Warts; Molluscum Contagiosum

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases; Poxviridae Infections

Central Study Contacts

Courtney Linkous, BA

CONTACT

843-566-2453; linkousc@musc.edu

Courtney Rowley

CONTACT

843-792-4349; rowle@musc.edu

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor, Dermatology and Dermatologic Surgery

Model Details: This is an open-label extension study. During a clinical care visit, if a patient is eligible and agrees to participate, lesions will be selected by the dermatologist prior to procedure. All lesions selected will be treated with non-thermal atmospheric plasma (NTAP).

Study Record Dates

• First Submitted: June 30, 2023
• First Posted: July 10, 2023
• Study Start: September 18, 2023
• Primary Completion: February 1, 2026
• Study Completion: February 1, 2026
• Last Updated: June 19, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)